219 related articles for article (PubMed ID: 34580930)
1. Efficacy and safety of conventional antiviral agents in preventive strategies for cytomegalovirus infection after kidney transplantation: a systematic review and network meta-analysis.
Ruenroengbun N; Numthavaj P; Sapankaew T; Chaiyakittisopon K; Ingsathit A; Mckay GJ; Attia J; Thakkinstian A
Transpl Int; 2021 Dec; 34(12):2720-2734. PubMed ID: 34580930
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Antiviral Agents in Preventing Allograft Rejection Following CMV Prophylaxis in High-Risk Kidney Transplantation: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Ruenroengbun N; Sapankaew T; Chaiyakittisopon K; Phoompoung P; Ngamprasertchai T
Front Cell Infect Microbiol; 2022; 12():865735. PubMed ID: 35433502
[TBL] [Abstract][Full Text] [Related]
3. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.
Hodson EM; Ladhani M; Webster AC; Strippoli GF; Craig JC
Cochrane Database Syst Rev; 2013 Feb; (2):CD003774. PubMed ID: 23450543
[TBL] [Abstract][Full Text] [Related]
4. Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients.
Noble S; Faulds D
Drugs; 1998 Jul; 56(1):115-46. PubMed ID: 9664203
[TBL] [Abstract][Full Text] [Related]
5. A split strategy to prevent cytomegalovirus after kidney transplantation using prophylaxis in serological high-risk patients and a pre-emptive strategy in intermediate-risk patients: Combining the best of two options?
Hellemans R; Wijtvliet V; Bergs K; Philipse E; Vleut R; Massart A; Couttenye MM; Matheeussen V; Abramowicz D
Transpl Infect Dis; 2021 Apr; 23(2):e13467. PubMed ID: 32935909
[TBL] [Abstract][Full Text] [Related]
6. Cytomegalovirus infection in heart transplantation: A single center experience.
Echenique IA; Angarone MP; Rich JD; Anderson AS; Stosor V
Transpl Infect Dis; 2018 Aug; 20(4):e12896. PubMed ID: 29602266
[TBL] [Abstract][Full Text] [Related]
7. Human cytomegalovirus and kidney transplantation: a clinician's update.
De Keyzer K; Van Laecke S; Peeters P; Vanholder R
Am J Kidney Dis; 2011 Jul; 58(1):118-26. PubMed ID: 21684438
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcomes of pre-emptive valganciclovir compared with valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation.
Reischig T; Hribova P; Jindra P; Hes O; Bouda M; Treska V; Viklicky O
J Am Soc Nephrol; 2012 Sep; 23(9):1588-97. PubMed ID: 22917575
[TBL] [Abstract][Full Text] [Related]
9. Impact of Prophylaxis vs Pre-emptive Approach for Cytomegalovirus Infection in Kidney Transplant Recipients.
Kır O; Zeytinoğlu A; Arda B; Yılmaz M; Aşçı G; Töz H
Transplant Proc; 2017 Apr; 49(3):537-540. PubMed ID: 28340829
[TBL] [Abstract][Full Text] [Related]
10. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.
Hodson EM; Barclay PG; Craig JC; Jones C; Kable K; Strippoli GF; Vimalachandra D; Webster AC
Cochrane Database Syst Rev; 2005 Oct; (4):CD003774. PubMed ID: 16235341
[TBL] [Abstract][Full Text] [Related]
11. Cytomegalovirus prevention strategies in seropositive kidney transplant recipients: an insight into current clinical practice.
Fernández-Ruiz M; Arias M; Campistol JM; Navarro D; Gómez-Huertas E; Gómez-Márquez G; Díaz JM; Hernández D; Bernal-Blanco G; Cofan F; Jimeno L; Franco-Esteve A; González E; Moreso FJ; Gómez-Alamillo C; Mendiluce A; Luna-Huerta E; Aguado JM;
Transpl Int; 2015 Sep; 28(9):1042-54. PubMed ID: 25864986
[TBL] [Abstract][Full Text] [Related]
12. Risk of cytomegalovirus disease in high-risk liver transplant recipients on valganciclovir prophylaxis: a systematic review and meta-analysis.
Kalil AC; Mindru C; Botha JF; Grant WJ; Mercer DF; Olivera MA; McCartan MA; McCashland TM; Langnas AN; Florescu DF
Liver Transpl; 2012 Dec; 18(12):1440-7. PubMed ID: 22887929
[TBL] [Abstract][Full Text] [Related]
13. Comparative Efficacy and Safety of Different Antiviral Agents for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis.
Gagelmann N; Ljungman P; Styczynski J; Kröger N
Biol Blood Marrow Transplant; 2018 Oct; 24(10):2101-2109. PubMed ID: 29777868
[TBL] [Abstract][Full Text] [Related]
14. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
Witzke O; Hauser IA; Bartels M; Wolf G; Wolters H; Nitschke M;
Transplantation; 2012 Jan; 93(1):61-8. PubMed ID: 22094954
[TBL] [Abstract][Full Text] [Related]
15. Cytomegalovirus High-risk Kidney Transplant Recipients Show No Difference in Long-term Outcomes Following Preemptive Versus Prophylactic Management.
Blom KB; Birkeland GK; Midtvedt K; Jenssen TG; Reisæter AV; Rollag H; Hartmann A; Sagedal S; Sjaastad I; Tylden G; Njølstad G; Nilsen E; Christensen A; Åsberg A; Birkeland JA
Transplantation; 2023 Aug; 107(8):1846-1853. PubMed ID: 37211633
[TBL] [Abstract][Full Text] [Related]
16. New developments in the management of cytomegalovirus infection after solid organ transplantation.
Eid AJ; Razonable RR
Drugs; 2010 May; 70(8):965-81. PubMed ID: 20481654
[TBL] [Abstract][Full Text] [Related]
17. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.
Hodson EM; Craig JC; Strippoli GF; Webster AC
Cochrane Database Syst Rev; 2008 Apr; (2):CD003774. PubMed ID: 18425894
[TBL] [Abstract][Full Text] [Related]
18. Valganciclovir prophylaxis in patients at high risk for the development of cytomegalovirus disease.
Taber DJ; Ashcraft E; Baillie GM; Berkman S; Rogers J; Baliga PK; Rajagopalan PR; Lin A; Emovon O; Afzal F; Chavin KD
Transpl Infect Dis; 2004 Sep; 6(3):101-9. PubMed ID: 15569225
[TBL] [Abstract][Full Text] [Related]
19. Pre-emptive intravenous ganciclovir versus valganciclovir prophylaxis for de novo cytomegalovirus-seropositive kidney-transplant recipients.
Weclawiak H; Kamar N; Mengelle C; Esposito L; Mohamed AO; Lavayssiere L; Ribes D; Cointault O; Nogier MB; Cardeau-Desangles I; Izopet J; Rostaing L
Transpl Int; 2010 Oct; 23(10):1056-64. PubMed ID: 20477997
[TBL] [Abstract][Full Text] [Related]
20. Intragraft cytomegalovirus infection: a randomized trial of valacyclovir prophylaxis versus pre-emptive therapy in renal transplant recipients.
Reischig T; Nemcová J; Vanecek T; Jindra P; Hes O; Bouda M; Treska V
Antivir Ther; 2010; 15(1):23-30. PubMed ID: 20167988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
